Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tobira Says Secondary Endpoint In NASH Will Carry CVC Into Pivotal Study

Executive Summary

The biotech argues that success in reducing fibrosis is more important than the failed primary endpoint measuring NAFLD activity score improvement – and also meets FDA's expectations – but the firm is taking a beating nonetheless.


Related Content

Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit
Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?
Endpoint Selection Could Help Determine The NASH Race
Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Tobira, Dong-A Stick To NASH Plans Despite CENTAUR Results
With 29 Candidates Advancing, NASH Race May Hinge On Long-Duration Data
Intercept’s Phase III Endpoints May Not Apply To Other Firms’ NASH Programs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts